<DOC>
	<DOC>NCT02754882</DOC>
	<brief_summary>This study is designed to establish biosimilarity of SB8, a proposed biosimilar product of bevacizumab, to EU-sourced bevacizumab, in patients with metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC).</brief_summary>
	<brief_title>A Study Comparing SB8 and Avastin® in Patients With Advanced Non-squamous Non-small Cell Lung Cancer</brief_title>
	<detailed_description>Standard efficacy parameters, safety profiles, pharmacokinetics and immunogenicity will be compared between SB8 and bevacizumab.</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1. Aged ≥ 18 years 2. ECOG performance status of 01 3. Histologicallyconfirmed metastatic or recurrent nonsquamous nonsmall cell lung cancer 4. At least one measurable lesion according to RECIST v1.1. 5. Able to receive bevacizumab, carboplatin and paclitaxel based on adequate laboratory and clinical parameters 1. Diagnosis of small cell carcinoma of the lung or squamous cell carcinoma 2. Sensitizing EGFR mutations or ALK rearrangements 3. Increased risk of bleeding determined by investigator based on radiographic / clinical findings 4. History of systemic chemotherapy administered in the firstline setting for metastatic or recurrent disease of NSCLC.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>avastin</keyword>
</DOC>